Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
10-01-04 Long-term control of gout
| Febuxostat |
|
Second Choice
|
Tablets 80mg, 120mg |
 MHRA: Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity MHRA: Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease |
|
Links
LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA advice regarding risk of serious hypersensitivity reactions
- MHRA Drug Safety update July 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
- MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Colchicine: extremely toxic in overdose
- MHRA: Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity
- MHRA: Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE HST25 - Lumasiran for treating primary hyperoxaluria type 1
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA164: Hyperuricaemia - febuxostat
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)